UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B
UCB→Neurona Therapeutics
Apr 17, 2026

Channel-specific outreach playbooks for deal origination.
Comparison posts, methodology, and analysis from the Tentt team.
Monthly market reports on M&A and private equity activity.
Free calculators for M&A, lending, and deal analysis.
Origination in the Age of AI.
Panthera Biopartners announced it has acquired OEC, described as Hungary’s leading clinical research organisation, to expand its European footprint. The deal is positioned as a platform expansion in healthcare services.
The provided materials do not disclose deal value, closing timing, or the specific transaction structure beyond the acquisition announcement. OEC is characterized as a clinical research organisation based in Hungary.
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
UCB→Neurona Therapeutics
Apr 17, 2026
Jackson Memorial Hospital
Apr 17, 2026
Kailera Therapeutics
Apr 17, 2026
Gilead→Arcellx
Apr 17, 2026
Lilly→Centessa Pharmaceuticals
Apr 17, 2026